[go: up one dir, main page]

MX2019015747A - Compuesto heterociclico. - Google Patents

Compuesto heterociclico.

Info

Publication number
MX2019015747A
MX2019015747A MX2019015747A MX2019015747A MX2019015747A MX 2019015747 A MX2019015747 A MX 2019015747A MX 2019015747 A MX2019015747 A MX 2019015747A MX 2019015747 A MX2019015747 A MX 2019015747A MX 2019015747 A MX2019015747 A MX 2019015747A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
formula
present
compound
constipation
Prior art date
Application number
MX2019015747A
Other languages
English (en)
Other versions
MX390752B (es
Inventor
Ando Haruhi
Yamada Masami
Fujimori Ikuo
Takami Kazuaki
Shimokawa Kenichiro
Ogino Masaki
Murakami Masataka
Yonemori Jinichi
Okawa Tomohiro
Seto Masaki
Sasaki Shinobu
Ohashi Tomoko
Imaeda Toshihiro
Tsukimi Yasuhiro
Wakabayashi Takeshi
Fushimi Makoto
Suzuki Hideo
Maezaki Hironobu
Sato Ayumu
Asano Yasutomi
Swann Steve
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Priority claimed from PCT/JP2018/023357 external-priority patent/WO2018235838A1/ja
Publication of MX2019015747A publication Critical patent/MX2019015747A/es
Publication of MX390752B publication Critical patent/MX390752B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención tiene como objetivo proporcionar un compuesto que puede ser útil para la profilaxis o tratamiento del estreñimiento y similares. La presente invención proporciona un compuesto representado por la siguiente fórmula (I): (ver Fórmula) en donde cada símbolo es como se describe en la especificación, o una sal del mismo.
MX2019015747A 2017-06-20 2018-06-19 Compuesto heterociclico. MX390752B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017120859 2017-06-20
JP2018005960 2018-01-17
US201862683418P 2018-06-11 2018-06-11
PCT/JP2018/023357 WO2018235838A1 (ja) 2017-06-20 2018-06-19 複素環化合物

Publications (2)

Publication Number Publication Date
MX2019015747A true MX2019015747A (es) 2020-02-20
MX390752B MX390752B (es) 2025-03-21

Family

ID=69178190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015747A MX390752B (es) 2017-06-20 2018-06-19 Compuesto heterociclico.

Country Status (8)

Country Link
EP (1) EP3643718B1 (es)
JP (1) JP7123042B2 (es)
KR (1) KR102658949B1 (es)
CN (1) CN110709401B (es)
AU (1) AU2018289939B2 (es)
BR (1) BR112019026096A2 (es)
CA (1) CA3068209A1 (es)
MX (1) MX390752B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3858823A4 (en) * 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
CN114958325B (zh) * 2021-02-24 2023-06-27 中国石油化工股份有限公司 一种耐高温缓蚀剂、制备方法及其在井筒防腐中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4710445B2 (ja) 2004-07-08 2011-06-29 田辺三菱製薬株式会社 医薬組成物
ES2575154T3 (es) 2009-12-17 2016-06-24 Merck Sharp & Dohme Corp. Moduladores alostéricos positivos del receptor M1 de quinolina amida
EP2821401B1 (en) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
EP2921480B1 (en) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015163485A1 (en) 2014-04-23 2015-10-29 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease
JP6531093B2 (ja) 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
JP6571077B2 (ja) 2014-06-13 2019-09-04 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
MX385975B (es) 2016-02-16 2025-03-18 Univ Vanderbilt Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1.
ES2824495T3 (es) * 2016-09-02 2021-05-12 Suven Life Sciences Ltd Moduladores alostéricos positivos del receptor muscarínico M1

Also Published As

Publication number Publication date
AU2018289939B2 (en) 2022-06-16
EP3643718A4 (en) 2021-03-03
KR20200013773A (ko) 2020-02-07
MX390752B (es) 2025-03-21
RU2019140596A (ru) 2021-07-20
EP3643718A1 (en) 2020-04-29
CN110709401A (zh) 2020-01-17
EP3643718B1 (en) 2023-07-26
BR112019026096A2 (pt) 2020-07-07
JPWO2018235838A1 (ja) 2020-04-16
AU2018289939A1 (en) 2020-01-30
JP7123042B2 (ja) 2022-08-22
CN110709401B (zh) 2023-06-13
RU2019140596A3 (es) 2021-10-08
KR102658949B1 (ko) 2024-04-18
CA3068209A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
SG11201901061QA (en) Heterocyclic compound
MX2021015514A (es) Compuesto heterociclico.
ZA201701299B (en) Glycosidase inhibitors
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2018010192A (es) Inhibidores de glucosidasa.
PH12016500225B1 (en) Novel quinoline-substituted compound
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12019502248A1 (en) Ip6k inhibitors
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
PH12015501038A1 (en) Inhibitors of iap
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
GEP20186893B (en) Pyrazines modulators of gpr6
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MY193239A (en) Novel b-lactamase inhibitors
MX2021003481A (es) Compuesto heterociclico.
AU2016363719A8 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2019015747A (es) Compuesto heterociclico.
MX2019009362A (es) Compuestos heterociclicos novedosos y sus usos en la prevencion o el tratamiento de infecciones bacterianas.
MY199524A (en) Anti-angiogenic agents and uses thereof